Posting of Annual Report and Notice of AGM

Avacta Group PLC

02 June 2023

 

02 June 2023

Avacta Group plc

("Avacta" or the "Company" and, together with its subsidiary undertakings, the "Group")

Posting of Annual Report and Notice of AGM

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that its Annual Report and Accounts for the year ended 31 December 2022 and the Notice of the 2023 Annual General Meeting ("AGM") are now available on the Company's website at www.avacta.com/investors/documents.

Copies of the Annual Report and Accounts and the Notice of the AGM have been posted to registered shareholders who have elected to receive them in paper form.

The Annual General Meeting will be held on Wednesday, 28 June 2023 at 10.30 a.m. BST at The Royal Society of Medicine, 1 Wimpole Street, Westminster, London W1G 0AE (the "Venue").

The Venue has a capacity of approximately 140 people. Registered shareholders have a right to attend the AGM.  In addition, the current expectation is that the chair of the AGM will, at their discretion, permit beneficial shareholders to attend in person. Shareholders (registered or beneficial) who propose to attend the AGM in person are requested to pre-register their interest and, to assist the Company in its preparation for the AGM, prove their shareholding by emailing FTI Consulting at [e-mail] by 10:30 a.m. BST on 27 June 2023. Any failure to pre-register will not, of itself, preclude a registered shareholder from attending the AGM in person (or by proxy).

Only registered shareholders who attend in person or by proxy will be able to vote on the day. Details of how to submit a proxy vote are contained in the Notice of the AGM.

The Company will provide a business update following the AGM, which will be streamed live on the Investor Meet Company platform. Investors who already follow Avacta on Investor Meet Company will automatically be invited to join the live stream. Investors who do not have an Investor Meet Company account can sign up for free via the following link https://www.investormeetcompany.com/avacta-group-plc/register-investor and then click "Add to meet" Avacta Group in order to receive an invitation for the live stream. Those attending in person will be able to meet with a range of Avacta staff, view recently presented data posters and hear additional technical presentations.

Early pre-registration to attend the AGM in person is recommended as the Venue's capacity is limited (as referred to above) and, for non-registered shareholders, registrations will be dealt with on a first come, first served basis.

All presentation materials will be made available on the website at the end of the day and no new material information will be provided.

-Ends-

For further information from Avacta Group plc, please contact:

Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer Michael Vinegrad, Group Communications Director	Tel: [phone] www.avacta.com
Stifel Nicolaus Europe Limited (Nomad and Broker) Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Dhiren Suares / William Palmer-Brown	Tel: [phone] www.stifel.com
FTI Consulting (Financial Media and IR) Simon Conway / Alex Shaw	Tel: [phone] [e-mail]
Zyme Communications (Trade and Regional Media) Lily Jeffery	Tel: [phone] [e-mail]

About Avacta Group plc - www.avacta.com

Avacta Group plc is a life sciences company working to improve people's health and well-being through innovative oncology drugs and powerful diagnostics. Operating through two divisions, Diagnostics and Therapeutics, the Group's mission is to provide professionals and consumers with solutions that improve healthcare, fitness and well-being.

Avacta's Therapeutics Division, a clinical stage oncology drug innovator, is building a wholly owned pipeline of novel Affimer^® immunotherapies and pre|CISION™ tumour targeted chemotherapies. This approach is designed to address the lack of a durable response to current cancer immunotherapies experienced by most patients and reduce the severe systemic toxicities caused by chemotherapies. There are five programmes in the pipeline as well as several global research collaborations and licensing partnerships. Avacta's lead programme, AVA6000, is a pre|CISION™ tumour-targeted form of the established chemotherapy doxorubicin. AVA6000 is in Phase I clinical trials in patients with locally advanced or metastatic selected solid tumours.

The Affimer^® platform is an alternative to antibodies that has been designed to address many of the drawbacks of antibodies which, despite their shortcomings, currently dominate the immuno-diagnostics and immuno-therapeutics markets.

The pre|CISION™ tumour targeting platform can be used to modify a chemotherapy in order to selectively release the active drug in tumour tissue thereby reducing the systemic exposure that causes damage to healthy tissues. pre|CISION™ modified chemotherapies are designed to reduce the side effects and improve the overall safety and therapeutic potential of these powerful anti-cancer treatments.

Avacta's Diagnostics Division develops and supplies a broad range of in-vitro diagnostic (IVD) solutions. The Division is growing rapidly through an M&A strategy to deliver a global scale IVD business providing market leading solutions for healthcare professionals and consumers to inform treatment and monitor health and well-being. In October 2022, Avacta acquired Launch Diagnostics which serves the hospital pathology laboratory market in the UK and Europe. In May 2023, Avacta acquired Coris Bioconcept a Belgium based lateral flow test developer and manufacturer adding a broad range of marketed professional-use rapid tests into the Diagnostics Division. Avacta Diagnostic's research and development centre in Wetherby, UK uses its proprietary Affimer^® platform to differentiate immunodiagnostic products to provide marketing leading performance.

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

 

END